C5a complement levels in clinical remission AQP4-IgG-positive NMO patients.
Analisa ManinMariano E JustoJuliana LeoniMariela L PazAndres M VillaPublished in: Acta neurologica Belgica (2023)
In conclusion, the present study demonstrates that plasma C5a may be interesting to investigate as a potential biomarker of disease activity in NMOSD, in a larger and prospective cohort.